Galectin Therapeutics Inc. (NASDAQ:GALT - Get Free Report) major shareholder James C. Czirr sold 21,323 shares of the company's stock in a transaction dated Monday, April 22nd. The shares were sold at an average price of $3.06, for a total transaction of $65,248.38. Following the completion of the sale, the insider now directly owns 5,925,884 shares of the company's stock, valued at $18,133,205.04. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Large shareholders that own 10% or more of a company's stock are required to disclose their transactions with the SEC.
Galectin Therapeutics Stock Up 6.4 %
GALT stock opened at $3.50 on Friday. Galectin Therapeutics Inc. has a one year low of $1.28 and a one year high of $4.27. The firm has a 50-day moving average of $2.54 and a two-hundred day moving average of $2.10.
Galectin Therapeutics (NASDAQ:GALT - Get Free Report) last posted its quarterly earnings data on Friday, March 29th. The company reported ($0.16) EPS for the quarter. As a group, equities research analysts predict that Galectin Therapeutics Inc. will post -0.66 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Rich Dad Poor Dad Author Shocks Millions With 2024 Crash Warning
From American Hartford Gold Group | Ad
Dave Ramsey Is Dangerously Wrong And Here’s Why>>
Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air:
“Am I worried about this? Absolutely not.”
Frankly, I've never seen someone so confident in being wrong…
Because what’s happening to the US Dollar is not something you should “keep an eye on”…
But instead, is an imminent threat you should get ahead of right NOW.
GET THE FREE GUIDE
A number of equities research analysts have weighed in on GALT shares. HC Wainwright reissued a "buy" rating and issued a $11.00 price target on shares of Galectin Therapeutics in a report on Tuesday, April 9th. StockNews.com raised shares of Galectin Therapeutics from a "sell" rating to a "hold" rating in a report on Monday, April 1st.
Read Our Latest Stock Analysis on Galectin Therapeutics
Institutional Trading of Galectin Therapeutics
A number of hedge funds have recently bought and sold shares of GALT. Solutions 4 Wealth Ltd purchased a new stake in Galectin Therapeutics during the fourth quarter valued at about $60,000. Retirement Guys Formula LLC increased its holdings in shares of Galectin Therapeutics by 56.9% in the 1st quarter. Retirement Guys Formula LLC now owns 33,732 shares of the company's stock valued at $81,000 after purchasing an additional 12,232 shares during the period. AE Wealth Management LLC increased its holdings in shares of Galectin Therapeutics by 72.7% in the 3rd quarter. AE Wealth Management LLC now owns 26,841 shares of the company's stock valued at $52,000 after purchasing an additional 11,300 shares during the period. Beacon Capital Management LLC increased its holdings in shares of Galectin Therapeutics by 89.6% in the 4th quarter. Beacon Capital Management LLC now owns 23,905 shares of the company's stock valued at $40,000 after purchasing an additional 11,300 shares during the period. Finally, D.A. Davidson & CO. increased its holdings in shares of Galectin Therapeutics by 15.2% in the 3rd quarter. D.A. Davidson & CO. now owns 37,825 shares of the company's stock valued at $73,000 after purchasing an additional 5,000 shares during the period. 11.68% of the stock is owned by hedge funds and other institutional investors.
Galectin Therapeutics Company Profile
(
Get Free Report)
Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
